Prevalence and outcomes of atrial fibrillation in patients hospitalized with COVID-19
Creators: name: Vaidean, Georgeta D.
name: Rubens, Muni
name: Ramamoorthy, Venkataraghavan
name: Saxena, Anshul
name: Appunni, Sandeep
name: Khosla, Atulya Aman
name: Doke, Mayur
name: Körfer, Daniel
name: Chaparro, Sandra
name: Jimenez, Javier
Publisher: name: Taylor & Francis
Year: 2024
Subjects: Medicine
Biotechnology
Marine Biology
Science Policy

description: Atrial fibrillation (AF) is a common arrhythmia in patients at high cardiovascular risk. COVID-19 patients with underlying cardiovascular disease are at increased risk of poor clinical outcomes. In this study, we aimed to determine hospital outcomes among patients admitted with AF and COVID-19 infection. We conducted a retrospective analysis using the 2020 California State Inpatient data, including all COVID-19 hospitalizations of individuals aged ≥18. Primary outcomes were in-hospital mortality, prolonged length of stay (above the 75th percentile), vasopressor use, mechanical ventilation, and ICU admission. We compared adverse hospital outcomes between those with and without AF and used multivariable logistic regression to adjust for confounders. This analysis included 94,114 COVID-19 hospitalizations, of which 9391 (10.0%) had AF. Patients with COVID-19 and AF had higher rates of adverse outcomes, including mortality (27.2% vs. 9.6%, <i>p</i> &lt; .001), prolonged length of stay (40.0% vs. 27.1%, <i>p</i> &lt; .001), vasopressor use (4.4% vs. 1.9%, <i>p</i> &lt; .001), mechanical ventilation (19.0% vs. 9.1%, <i>p</i> &lt; .001), and ICU admission (18.4% vs. 8.8%, <i>p</i> &lt; .001) After multivariable adjustment, the odds of adverse outcomes remained significantly higher, including mortality adjusted odds ratio [OR], 2.04, 95% CI: 1.92–2.16), prolonged length of stay (aOR, 1.37, 95% CI: 1.31–1.44), vasopressor use (aOR, 1.98, 95% CI: 1.86–2.11), mechanical ventilation (aOR, 1.95, 95% CI: 1.72–2.20), and ICU admission (aOR, 2.01, 95% CI: 1.88–2.15). COVID-19 hospitalized patients frequently have underlying AF, which confers a higher risk of adverse hospital outcomes and mortality, even after adjusting for baseline comorbidities. Heightened awareness is needed in the treatment of hospitalized COVID-19 patients with AF. Atrial fibrillation (AF) is a common heart rhythm disorder, especially in patients with high cardiovascular risk. This study aimed to investigate the hospital outcomes for patients admitted with both AF and COVID-19. We used data from the California State Inpatient Database for the year 2020, focusing on COVID-19 hospitalizations of adults aged 18 and older. The main outcomes studied were in-hospital death, extended hospital stays, use of vasopressor medications that raise blood pressure, need for mechanical ventilation, and admission to the intensive care unit (ICU). Our results showed that patients with both COVID-19 and AF had significantly worse outcomes compared to those without AF. Specifically, these patients had higher rates of death, extended hospital stays, vasopressor medication use, mechanical ventilation, and ICU admission, even after accounting for other health conditions. The study concludes that hospitalized COVID-19 patients with underlying AF are at a greater risk for severe complications and death. This highlights the need for increased attention and care for COVID-19 patients with AF to improve their hospital outcomes.